Apixaban Drug Profile

What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) that belongs to a class of medications called factor Xa inhibitors. It is primarily used to prevent blood clots and reduce the risk of stroke in patients with certain heart rhythm disorders and other clotting conditions. Unlike traditional blood thinners like warfarin, apixaban does not require routine blood monitoring.

Uses

• Stroke prevention in atrial fibrillation: Reduces stroke risk in patients with non-valvular atrial fibrillation by preventing clot formation in the heart
• Deep vein thrombosis (DVT) treatment: Treats existing blood clots in the deep veins, typically in the legs
• Pulmonary embolism (PE) treatment: Treats blood clots that have traveled to the lungs
• DVT and PE prevention: Prevents recurrence of venous blood clots after initial treatment
• Post-surgical clot prevention: Reduces risk of blood clots following hip or knee replacement surgery

How it works

Apixaban works by directly blocking factor Xa, a key enzyme in the blood clotting cascade. By inhibiting this enzyme, the medication prevents the formation of thrombin, which is essential for converting fibrinogen into fibrin—the protein that forms blood clots. This action reduces the blood’s ability to form harmful clots while maintaining some clotting function for normal wound healing.

Side effects

Common side effects:

• Easy bruising
• Minor bleeding (nosebleeds, gum bleeding)
• Fatigue
• Nausea
• Skin rash
• Dizziness
• Headache
• Joint pain

Serious side effects requiring immediate medical attention:

Submit Your Paper

• Major bleeding (gastrointestinal, brain, or other internal bleeding)
• Unusual or prolonged bleeding
• Signs of severe allergic reaction (difficulty breathing, swelling of face or throat)
• Black or bloody stools
• Vomiting blood or coffee-ground material

Warnings and precautions

• Bleeding risk: Patients with active bleeding, recent surgery, or high bleeding risk should avoid apixaban or use it with extreme caution under close medical supervision
• Kidney function: Dose adjustment or avoidance may be necessary in patients with severe kidney disease, as reduced kidney function can increase drug levels and bleeding risk
• Pregnancy and breastfeeding: Safety during pregnancy has not been established; the medication may increase bleeding risk during delivery and should only be used when benefits clearly outweigh risks
• Liver disease: Patients with moderate to severe liver impairment should avoid apixaban due to increased bleeding risk and altered drug metabolism
• Surgery and procedures: The medication should be temporarily discontinued before elective surgery or invasive procedures to reduce bleeding complications

Interactions

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir): Significantly increase apixaban levels, raising bleeding risk
• Strong CYP3A4 inducers (rifampin, phenytoin): Decrease apixaban effectiveness by reducing drug levels
• Other anticoagulants (warfarin, heparin): Increase bleeding risk when used together
• Antiplatelet agents (aspirin, clopidogrel): Enhance bleeding risk through additive anticoagulant effects
• NSAIDs (ibuprofen, naproxen): May increase bleeding risk, especially gastrointestinal bleeding
• St. John’s wort: May reduce apixaban effectiveness by increasing drug metabolism
• Dual P-gp and strong CYP3A4 inhibitors: Create particularly high risk of excessive drug accumulation
• Fibrinolytic agents: Dramatically increase bleeding risk when combined with apixaban

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosages vary by indication: for stroke prevention in atrial fibrillation, the usual dose is 5 mg twice daily, reduced to 2.5 mg twice daily in patients who are elderly, have low body weight, or reduced kidney function. For DVT and PE treatment, the standard regimen is 10 mg twice daily for the first 7 days, followed by 5 mg twice daily. For prevention of recurrent clots, 2.5 mg twice daily is typically prescribed. Post-surgical prophylaxis usually involves 2.5 mg twice daily starting 12-24 hours after surgery. All dosages should be individualized and determined by a healthcare provider based on patient-specific factors including kidney function, age, weight, and bleeding risk.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).